Semaglutide vs NAD+ (Nicotinamide Adenine Dinucleotide)
Head-to-head comparison of Semaglutide and NAD+ (Nicotinamide Adenine Dinucleotide) for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Semaglutide | Nad Plus |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Anti-Aging / Telomere |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | Functions as: (1) an electron carrier in glycolysis, TCA cycle, and oxidative phosphorylation; (2) a substrate for sirtuins (SIRT1-7), which regulate gene expression, DNA repair, and metabolism; (3) a substrate for PARPs, which repair DNA damage; (4) a substrate for CD38/CD157, involved in calcium signaling and immune function. |
| Evidence Rating | A — FDA Approved | C — Early Human / Mixed Evidence |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | NAD+ IV: used clinically at anti-aging and addiction clinics; no FDA approval. NMN: Phase I/II human trials completed (Yoshino et al., Science 2021). NR: multiple human trials completed. |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent; Rare tachycardia and blood pressure changes during IV infusion |
| Molecular Weight | ~4113.6 g/mol | 663.43 g/mol |
| Half-Life | ~160–168 hours (~7 days) | ~30 minutes (IV plasma); intracellular NAD+ turnover ~6-10 hours |
Overview
Semaglutide and NAD+ (Nicotinamide Adenine Dinucleotide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
NAD+ (Nicotinamide Adenine Dinucleotide) — Mechanism & Evidence
NAD+ is a fundamental coenzyme present in all living cells that serves as a critical electron carrier in metabolic reactions and a substrate for enzymes including sirtuins, PARPs, and CD38. NAD+ levels decline approximately 50% between ages 40 and 60. While not a peptide, NAD+ and its precursors (NMN, NR) are frequently discussed in peptide communities. IV NAD+ infusions are popular at anti-aging clinics, though large-scale human efficacy trials are limited.
Key claims: IV NAD+ restores youthful cellular function; NAD+ precursors (NMN/NR) slow aging; Helps with addiction and withdrawal.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Semaglutide is also researched for: Weight Management, Cardiovascular.
NAD+ (Nicotinamide Adenine Dinucleotide) is also researched for: Anti-Aging & Longevity.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
NAD+ (Nicotinamide Adenine Dinucleotide): IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent Rare tachycardia and blood pressure changes during IV infusion Theoretical concern: NAD+ is used by cancer cells; boosting NAD+ in the presence of occult malignancy could promote tumor progression
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Semaglutide News: New Meta-Analysis Highlights Weight and Inflammatory Benefits
A recent systematic review and meta-analysis examines the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Early reports suggest meaningful reductions in body weight alongside improvements in inflammatory biomarkers, offering new context for peptide researchers and industry professionals.
Semaglutide News: How Long to Lose 30 Pounds on Semaglutide?
A common question in the semaglutide news cycle is how long it takes to lose 30 pounds on the medication. While individual results vary, clinical trial data and prescribing guidelines offer a general timeline. This article breaks down the expected weight loss trajectory and what factors influence the pace.
Semaglutide News 2026: How to Calculate Peptide Reconstitution
As semaglutide news 2026 continues to generate interest among researchers, understanding how to calculate reconstitution for peptides is essential. This guide covers the math, safety, and practical steps for accurate peptide preparation.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe